From Analysis:
How does the intron-retained RNA isoform mechanistically reduce glucocerebrosidase protein levels and activity?
Retained introns contain upstream ORFs or alternative start sites producing N-terminal peptides that contain signal sequences directing co-translational ER targeting. These aberrant peptides outcompete wild-type GBA nascent chains for SRP binding, preventing proper ER targeting of wild-type GBA. Without SRP-mediated targeting, wild-type GBA misfolds in the cytosol and is degraded by proteasome. Lysosomal delivery of residual GBA is impaired due to disrupted mannose-6-phosphate tagging. Importantly, LIMP-2 enhancement represents a therapeutic strategy independent of upstream mechanism validation.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["SRP54/SRP68/SRP72
Signal Recognition Particle"]
B["Co-Translational
ER Targeting Defect"]
C["SCARB2 (LIMP2)
Lysosomal Targeting"]
D["Lysosomal
Proteostasis Failure"]
E["Proteostatic
Stress"]
F["ER
Associated Degradation"]
G["Neurodegeneration
Protein Misfolding"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
The research question addresses how a specific intron-retaining transcript of GBA (glucosylceramidase, the gene mutated in Gaucher disease) leads to reduced protein levels and enzymatic activity—a phenomenon particularly relevant given that GBA haploinsufficiency is a major Parkinson's disease risk factor.
Title: Cytoplasmic Intron-Retained GBA Transcripts Stall Ribosomes, Activating Collisional Quality Control That Glob
Based on the critique revision, the hypotheses with sufficient mechanistic support to warrant drug development consideration are:
| Rank | Hypothesis | Revised Confidence | Strategic Priority |
|------|-----------|-------------------|-------------------|
| 1 | RBP Sequestration (H6) | 0.58 | High — neuronal context, established targets |
| 2 | Ribosome Stalling (H1) | 0.52 | High — measurable, actionable pathway |
| 3 | SRP Interference (H7) | 0.52 | Moderate — signal peptide biology is
{"ranked_hypotheses":[{"title":"Dominant-Negative Spliceosome Titration","description":"Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects prot
No price history recorded yet
No clinical trials data available
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
No related hypotheses found
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
GBA_intron_retained_trans["GBA intron-retained transcript"] -->|sequesters| U2AF2["U2AF2"]
GBA_intron_retained_trans_1["GBA intron-retained transcript"] -->|sequesters| SF3B1["SF3B1"]
GBA_intron_retained_trans_2["GBA intron-retained transcript"] -->|sequesters| PRPF8["PRPF8"]
GBA_intron_retained_trans_3["GBA intron-retained transcript"] -->|activates collisio| ZNF598["ZNF598"]
GBA_intron_retained_trans_4["GBA intron-retained transcript"] -->|recruits| GIGYF2["GIGYF2"]
TARDBP__TDP_43__aggregati["TARDBP (TDP-43) aggregation"] -->|disrupts| GBA_intron_retention_clea["GBA intron retention clearance"]
FMR1__FMRP_["FMR1 (FMRP)"] -->|regulates translat| GBA_mRNA["GBA mRNA"]
ELAVL1__HuR_["ELAVL1 (HuR)"] -->|stabilizes| GBA_mRNA_5["GBA mRNA"]
SCARB2__LIMP_2_["SCARB2 (LIMP-2)"] -->|lysosomal traffick| GBA_protein["GBA protein"]
EIF2AK3__PERK_["EIF2AK3 (PERK)"] -->|phosphorylates| EIF2S1__eIF2__["EIF2S1 (eIF2α)"]
EIF2S1__eIF2___phosphoryl["EIF2S1 (eIF2α) phosphorylation"] -.->|suppresses| Cap_dependent_translation["Cap-dependent translation"]
SRP54["SRP54"] -->|recognizes for ER| GBA_signal_peptide["GBA signal peptide"]
style GBA_intron_retained_trans fill:#4fc3f7,stroke:#333,color:#000
style U2AF2 fill:#4fc3f7,stroke:#333,color:#000
style GBA_intron_retained_trans_1 fill:#4fc3f7,stroke:#333,color:#000
style SF3B1 fill:#4fc3f7,stroke:#333,color:#000
style GBA_intron_retained_trans_2 fill:#4fc3f7,stroke:#333,color:#000
style PRPF8 fill:#4fc3f7,stroke:#333,color:#000
style GBA_intron_retained_trans_3 fill:#4fc3f7,stroke:#333,color:#000
style ZNF598 fill:#4fc3f7,stroke:#333,color:#000
style GBA_intron_retained_trans_4 fill:#4fc3f7,stroke:#333,color:#000
style GIGYF2 fill:#4fc3f7,stroke:#333,color:#000
style TARDBP__TDP_43__aggregati fill:#4fc3f7,stroke:#333,color:#000
style GBA_intron_retention_clea fill:#4fc3f7,stroke:#333,color:#000
style FMR1__FMRP_ fill:#4fc3f7,stroke:#333,color:#000
style GBA_mRNA fill:#4fc3f7,stroke:#333,color:#000
style ELAVL1__HuR_ fill:#4fc3f7,stroke:#333,color:#000
style GBA_mRNA_5 fill:#4fc3f7,stroke:#333,color:#000
style SCARB2__LIMP_2_ fill:#4fc3f7,stroke:#333,color:#000
style GBA_protein fill:#4fc3f7,stroke:#333,color:#000
style EIF2AK3__PERK_ fill:#4fc3f7,stroke:#333,color:#000
style EIF2S1__eIF2__ fill:#4fc3f7,stroke:#333,color:#000
style EIF2S1__eIF2___phosphoryl fill:#4fc3f7,stroke:#333,color:#000
style Cap_dependent_translation fill:#4fc3f7,stroke:#333,color:#000
style SRP54 fill:#4fc3f7,stroke:#333,color:#000
style GBA_signal_peptide fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-26 | completed
No comments yet. Be the first to comment!